864 related articles for article (PubMed ID: 19460509)
21. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.
Vítko S; Klinger M; Salmela K; Wlodarczyk Z; Tydèn G; Senatorski G; Ostrowski M; Fauchald P; Kokot F; Stefoni S; Perner F; Claesson K; Castagneto M; Heemann U; Carmellini M; Squifflet JP; Weber M; Segoloni G; Bäckman L; Sperschneider H; Krämer BK
Transplantation; 2005 Dec; 80(12):1734-41. PubMed ID: 16378069
[TBL] [Abstract][Full Text] [Related]
22. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
[TBL] [Abstract][Full Text] [Related]
24. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
[TBL] [Abstract][Full Text] [Related]
25. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
26. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
Kovac D; Kotnik V; Kandus A
Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
[TBL] [Abstract][Full Text] [Related]
27. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
28. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
[TBL] [Abstract][Full Text] [Related]
29. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
[TBL] [Abstract][Full Text] [Related]
31. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
32. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients.
Sessa A; Esposito A; Giliberti A; Iavicoli G; Costa C; Bergallo M; Lettieri E; Rossano R; Capuano M
Transplant Proc; 2009 May; 41(4):1178-82. PubMed ID: 19460510
[TBL] [Abstract][Full Text] [Related]
33. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
Stegall MD; Wachs ME; Everson G; Steinberg T; Bilir B; Shrestha R; Karrer F; Kam I
Transplantation; 1997 Dec; 64(12):1755-60. PubMed ID: 9422416
[TBL] [Abstract][Full Text] [Related]
34. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
[TBL] [Abstract][Full Text] [Related]
35. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
36. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
[TBL] [Abstract][Full Text] [Related]
39. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab.
Andrade-Sierra J; Rojas-Campos E; Cardona-Muñoz E; Evangelista-Carrillo LA; Puentes-Camacho A; Lugo-López O; Gómez B; Valdespino C; Cerrillos I; Medina-Pérez M; Jalomo B; Nieves JJ; Sandoval M; Ramos-Solano F; Monteón-Ramos F; Cueto-Manzano AM
Nefrologia; 2014; 34(2):216-22. PubMed ID: 24658197
[TBL] [Abstract][Full Text] [Related]
40. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
